Streetbeat News

Stock Prices

NTAP

NetApp, Inc. (NASDAQ:NTAP) exceeded third-quarter financial expectations, posting adjusted earnings of $1.94 per share against estimates of $1.69 and sales of $1.61 billion versus expected $1.591 billion. CEO George Kurian highlighted record profitability and a modern approach to data storage as key drivers. Fourth-quarter earnings are projected between $1.73 to $1.83 per share, with net revenues expected to be between $1.585 billion to $1.735 billion. Following the report, NetApp shares rose 1.2%, and analysts from Barclays, Evercore ISI Group, and TD Cowen raised their price targets for NTAP.

Portfolio Pulse from Avi Kapoor

March 01, 2024 | 1:12 pm

FSR

REAL

In Friday's pre-market session, several consumer discretionary stocks showed significant movement. Notably, J-Long Group, Sweetgreen, and RealReal experienced substantial gains, attributed to recent earnings reports for Sweetgreen and RealReal. Conversely, Fisker, REE Automotive, and Jakks Pacific were among the notable losers, with Fisker and Jakks Pacific's declines also linked to their latest earnings reports.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 1:10 pm

ADIL

BIVI

HUMA

SCLX

In Friday's pre-market session, several healthcare stocks showed significant movement. Adial Pharmaceuticals, BioVie, Bone Biologics, Y-mAbs Therapeutics, Cardiff Oncology, and Biodesix experienced notable gains, with increases ranging from 17.53% to 76.0%. On the downside, Scilex Holding, Humacyte, Gritstone Bio, Precision BioSciences, Vivani Medical, and DermTech saw declines between 16.41% and 35.7%. The movements were largely attributed to recent Q4 earnings reports.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 1:09 pm

BYU

DCFC

GWAV

NXU

SIDU

TGLS

In Friday's pre-market session, several industrials stocks showed significant movement. Notably, Nxu, Baiyu Holdings, and Greenwave Tech Solutions experienced substantial gains, while Sidus Space, Tritium DCFC, and Royalty Management Holdings faced notable declines. Tecnoglass's stock also decreased following their Q4 earnings release.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 1:09 pm

DELL

MINM

SOUN

In Friday's pre-market session, several Information Technology stocks showed significant movement. Minim, MMTEC, Dell Technologies, Everbridge, NetApp, and Navitas Semiconductor were among the gainers, with Minim leading by surging 67.4%. On the downside, SoundHound AI, Inuvo, WeTrade Group, Ascent Solar Technologies, Mobix Labs, and Zscaler experienced declines, with SoundHound AI dropping 18.9%. The movements were largely influenced by recent earnings reports.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 1:09 pm

AINC

Ashford Inc. (NYSE:AINC) announced that the NYSE American has accepted its compliance plan for continued listing, following a notification of non-compliance with listing standards related to stockholders' equity. The company has until June 20, 2025, to regain compliance, subject to quarterly reviews. Failure to meet the standards may result in delisting.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 1:05 pm

DAVA

Endava (NYSE:DAVA) has been analyzed by 7 analysts, showing a mix of bullish and indifferent sentiments. The average 12-month price target is $72.14, slightly up from $72.00. Analyst actions include both raises and lowers in ratings and price targets, reflecting changing market dynamics and company performance. Endava faces challenges with a -3.95% revenue decline, below-average net margin, ROE, and ROA, but maintains a prudent debt management strategy.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 1:01 pm

WNS

Recent analyst ratings for WNS (Hldgs) (NYSE:WNS) show a mix of bullish and bearish perspectives, with an average 12-month price target of $78.83, marking a 2.91% increase from the previous target. The company has shown positive financial performance, including a revenue growth rate of 6.28% and a net margin of 12.15%, outperforming industry averages.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 1:01 pm

FDMT

Analyst perspectives on 4D Molecular Therapeutics (NASDAQ:FDMT) show a mix of bullish and bearish views with 5 recent ratings. The average 12-month price target is $49.4, reflecting a 31.73% increase from the previous $37.50. Analysts from HC Wainwright & Co., Goldman Sachs, BMO Capital, and RBC Capital have provided updates, with price targets ranging from $25.00 to $81.00. 4D Molecular Therapeutics, a clinical-stage gene therapy company, has shown significant revenue growth and solid financial performance, with a notable market capitalization and positive indicators such as net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 1:01 pm

Analyst ratings for Colgate-Palmolive (NYSE:CL) have shown a positive trend over the past three months, with recent updates indicating a bullish outlook. The average 12-month price target has risen to $90.25, reflecting a 7.19% increase from the previous target. Analysts from firms like Goldman Sachs, Morgan Stanley, and UBS have raised their price targets, citing the company's strong market presence, revenue growth, and financial performance. Despite challenges in debt management, Colgate-Palmolive's revenue growth and profitability metrics stand out in the Consumer Staples sector.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 1:00 pm